Navigation Links
Researchers discover mutations linked to relapse of childhood leukemia
Date:2/3/2013

After an intensive three-year hunt through the genome, medical researchers have pinpointed mutations that leads to drug resistance and relapse in the most common type of childhood cancerthe first time anyone has linked the disease's reemergence to specific genetic anomalies.

The discovery, co-lead by William L. Carroll, MD, director of NYU Langone Medical Center's Cancer Institute, is reported in a study published online February 3, 2013, in Nature Genetics.

"There has been no progress in curing children who relapse, in spite of giving them very high doses of chemotherapy and bone marrow transplants," said Dr. Carroll.

The discovery suggests how scientists may be able to thwart a dangerous form of acute lymphoblastic leukemia, a rapidly progressing blood-borne cancer that strikes about 6,000 people in the United States every year and accounts for more than one in four pediatric cancers. Eventually, such information could help doctors detect the early emergence of chemotherapy-resistant leukemia cells in patients and switch to a different treatment strategy before the disease can fully reassert itself.

In acute lymphoblastic leukemia, abbreviated ALL, the body's bone marrow produces an abnormally large number of lymphocytes, or white blood cells. Improved treatments have increased the overall cure rate to roughly 80 percent. But Dr. Carroll says the prognosis is especially dire for some 20 percent of patients who relapse.

Medical researchers have suspected that the reemergence of disease could be due to drug resistance, but previous efforts had not uncovered any definitive pathway. For the new study, led by Dr. Carroll and graduate student Julia Meyer, researchers at five U.S. institutions spent three years analyzing multiple bone marrow samples from pediatric ALL patients for more clues to the disease's progression.

With the help of the Children's Oncology Group, a multi-institutional clinical trials consortium supported by the National Cancer Institute, the researchers analyzed the entire transcriptomeor the full sequence of RNA from 10 children with pediatric B lymphoblastic leukemia, the most common subtype of ALL. RNA is an essential intermediary in the cellular process that uses DNA blueprints to assemble specific proteins, thus a leukemia transcriptome gives researchers a view of all active genes within the cancerous cells.

For each patient, the team pieced together a complete sequence of RNA extracted from the bone marrow at three time points: at diagnosis, during remission, and upon relapse some months or years later. All told, the project required the researchers to sequence, or spell out, 100 billion letters of RNA. By comparing the before and after sequences, the team found that each patient had acquired between one and six mutations that changed the genetic code over the course of the disease. In some cases researchers were able to detect these mutations in a very small subset (0.01 percent) of the tissue samples at diagnosis so that these cells likely expanded because their drug resistant properties provided the leukemia cells with a survival advantage.

In all, the team documented 20 relapse-specific mutationsnone of which had previously been implicated in ALL recurrences. Intriguingly, two patients harbored a mutation in the same gene, NT5C2, which encodes a protein that normally regulates some building blocks used to construct DNA but also can degrade an important class of drugs called purine analogues used in ALL therapy.

When the researchers fully sequenced the NT5C2 gene in 61 other cases in which pediatric ALL patients had relapsed, they found five more mutations that altered the gene's coding region. Further experiments suggested that these NT5C2 mutations all increased the protein's enzymatic activity, making the cancer cells more resistant to a chemotherapy treatment designed to force the cells to kill themselves. All seven patients with NT5C2 mutations relapsed within three years of the initial diagnosisan early, particularly hard-to-treat re-emergence likely mediated by the drug resistance.

Armed with the new knowledge, Dr. Carroll says doctors may be better equipped to identify patients likely to relapse. "We plan to test the feasibility of screening patients during therapy using sophisticated sequencing technology to pick up low-level mutations in NT5C2 and other genes indicating that a mutant clone is growing," he says. His team is researching whether that advance warning could allow doctors to administer separate drugs to beat back the cancer cells, and is also working on a strategy to directly inhibit the mutant enzyme.


'/>"/>
Contact: Christopher Rucas
Christopher.Rucas@nyumc.org
212-404-3525
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers develop automated breast density test linked to cancer risk
2. Leading researchers warn of brain drain as scientists struggle to find funding
3. Researchers Identify Involuntary Tobacco Smoke Exposure in Boston Public Housing Authority Residents with Salivary Cotinine Testing from Salimetrics.
4. Researchers help confirm value of flow-diverting device for most challenging aneurysms
5. Researchers improve medical units to reduce nursing fatigue, cut costs
6. Researchers find gene that turns up effect of chemotherapy
7. Israeli researchers to participate in European Commission flagship
8. Tumor cells engineer acidity to drive cell invasion, Moffitt Cancer Center researchers say
9. Researchers say its time to treat anemia seriously
10. Rush researchers studying stem cell therapy to repair damaged knee cartilage
11. Researchers discover new mutations driving malignant melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , ... February 12, 2016 , ... Yisrayl Hawkins, Pastor ... article this week that uncovers what he says are the real facts surrounding all ... the Bible from parents and Sunday school teachers, and Yisrayl says there is more ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Dignity Health ... General Hospital Emergency Room –Mesa. The new facility is licensed under Dignity ... , “Dr. Bingham is an excellent leader and will ensure our new freestanding emergency ...
(Date:2/11/2016)... ... 11, 2016 , ... SPH Analytics announced today that ... health solutions, MDinsight® and IndiGO®, for its primary care clinicians. The 3-year partnership ... the contract were not disclosed. , As the healthcare market moves towards quality-based ...
(Date:2/11/2016)... Tampa, FL (PRWEB) , ... February 11, 2016 , ... ... Tampa Bay Lightning take on the St. Louis Blues at the Amalie Arena. The ... only portable, inflatable, walk-through heart exhibit, the MEGA Heart, prior to the game. The ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... ranked among the top five firms in the “2015/2016 Best in KLAS: Software ... and Staffing. KLAS is a research and insights firm on a global mission ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... February 11, 2016 Jeffrey Zucker ... Clinical Trials, will present at this year,s Summit for Clinical ... Regency in Miami, FL. Zucker will ... optimize study execution, supporting SCOPE,s "Improving Site Study Activation and ... on Thursday, Feb. 25 at 11:05 a.m. ...
(Date:2/11/2016)... 2016  Community pharmacists can help improve medication adherence ... through a custom-built medication synchronization program, Cardinal Health MedSync ... at Schieber Family Pharmacy in ... of patients enrolled in this medication synchronization program, which ... for the patient, and it,s a win for us ...
(Date:2/11/2016)... , Feb. 11, 2016  M3 Biotechnology Inc., spurred by a major "team investment" by ... brother, Michael, has completed an oversubscribed Series A-Round, according to CEO Leen Kawas , PhD. ... ... ... ...
Breaking Medicine Technology: